Antibodies

16 June 2023

AskGene IGCC 2023 Oral Presentation: Latest Results of ASKB589 Phase I/II Trial

16 June 2023

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria

16 June 2023

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

15 June 2023

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

15 June 2023

Hemab Therapeutics to Present New Preclinical Data on HMB-001 in Factor VII Deficiency and Initial Findings from Glanzmann Thrombasthenia Natural History Study at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress

15 June 2023

Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

15 June 2023

Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal

15 June 2023

Mabwell Announces the U.S. FDA approval of 9MW3811 for IND

15 June 2023

Aflibercept (Eylea) Biosimilars Pipeline Review

15 June 2023

AntlerA Norrin/Wnt-agonist ANT antibody enters clinical trials through a strategic partnership with EyeBio

15 June 2023

Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

13 June 2023

Ustekinumab (Stelara) Biosimilars Pipeline Review

13 June 2023

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

12 June 2023

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

12 June 2023

Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

11 June 2023

Thymic Stromal LymphoProtein (TSLP) Pipeline Review

11 June 2023

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

10 June 2023

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

10 June 2023

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress

9 June 2023

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

9 June 2023

Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases

9 June 2023

Astellas Submits New Drug Application for Zolbetuximab in Japan

9 June 2023

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

9 June 2023

ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

9 June 2023

Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023

9 June 2023

Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases

9 June 2023

IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy

9 June 2023

UCB Receives New European Commission Approvals for BIMZELX (bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

8 June 2023

FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer

8 June 2023

Samsung Bioepis Presents Population Pharmacokinetic (PK), Pharmacodynamic (PD), Efficacy Modeling of SB12 (Eculizumab), A Biosimilar to Soliris, at the European Hematology Association (EHA) Congress

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

5T4-Targeted Immunotherapy Candidates Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Report Package: “Drug the Undruggable” Technologies

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Bispecific Antibodies for Immuno-Oncology & Other Diseases